-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Lixte Biotechnology Holdings, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2022 to Q2 2024.
- Lixte Biotechnology Holdings, Inc. Earnings Per Share, Diluted for the quarter ending June 30, 2024 was -0.45 USD/shares, a 55% increase year-over-year.
- Lixte Biotechnology Holdings, Inc. Earnings Per Share, Diluted for the twelve months ending June 30, 2024 was -1.72 USD/shares.
- Lixte Biotechnology Holdings, Inc. annual Earnings Per Share, Diluted for 2023 was -2.66 USD/shares, a 33.3% increase from 2022.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)